You just read:

Shire Reports Top-line Results from Two Phase 3 Studies for Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) as an Adjunctive Treatment for Adults with Major Depressive Disorder

News provided by

Shire plc

06 Feb, 2014, 21:30 GMT